Nigeria: Subject-Matter Eligibility In AI & Medicine: The Nigerian Position – Olukolade Ehinmosan

Last Updated: 16 September 2019
Article by S.P.A. Ajibade & Co.

Olukolade O. Ehinmosan1

SUBJECT MATTER ELIGIBILITY IN AI & MEDICINE: THE NIGERIAN POSITION

Artificial Intelligence (AI) is no longer news. Over the past few decades, the increasing sophistication of digital technologies and AI have crept into the fields of finance, property and real estate and more related to this piece, the field of Medicine. Medical equipment, treatment Machines and computer algorithms are now more frequently designed and intelligently combined to exploit data for the production of meaningful medical outcomes such as the diagnoses of various ailments, therapeutic prescriptions, treatment and prediction of the outcome of clinical scenarios.2

A number of crucial intellectual property law issues arise with respect to AI inventions relating to the medical field. One of these issues is the eligibility of an invention for patentability under Nigerian Law as it relates to its subject matter. This article will address few global developments in AI and Medicine and examine this eligibility issue as it pertains to Nigerian Law.

  1. What is AI?

Arguably in its simplest form, programs or features which enable computers to function in ways similar to human or superhuman intelligence may be regarded as AI.3 AI is further defined as 'a field of science and engineering concerned with the computational understanding of what is commonly called Intelligent Behaviour, and with the creation of artefacts that exhibit such behaviour'.4

Alan Turing, British Mathematician reckoned for his founding and extensive works in modern computer science and AI defined Intelligent Behaviour in a computer as the ability to achieve human-level performance in cognitive tasks.5 As would be shown in this paper, AI achieves even super-human level performances and remains an emerging technological field with great and hair-splitting potentials.

Perhaps, AI is better understood in its practical and seemingly magical manifestations than its complex lexical representation. With the interaction of AI and Medicine in the solution of medical problems, AI would be more clearly relatable to the average individual.

  1. The Interaction of AI & Medicine

1976 heralded some amazement in the field of Surgery. A surgeon named Gunn explored the possibility of diagnosing acute abdominal pain using unaided or minimally aided computer analysis.6 This development marked the incipience of further massive AI inventions and discoveries. One of these inventions is the very popular Artificial Neural Networks (ANNs).

ANNs consist of networks of highly interconnected computer processors called 'neurons' capable of performing parallel computations for data processing and knowledge representations. ANNs are known to possess the ability to learn from historical examples, analyse non-linear data and handle imprecise information, rendering them invaluable in medical data analytics.7 ANNs are capable of conducting various medical diagnoses and prognosis as well as image analysis, data interpretation and waveform analysis.

In terms of diagnosis, a classification algorithm called ProstAsure Index was developed with the capability to classify prostate as either benign or malignant.8 Also, PAPNET, a computerized automated screening system based on ANNs has been developed to assist in cervical screening.

Another example suffices in the operation of Medical Chatbots. Medical Chatbots utilize neural networks to learn from medical textbooks, scientific research, patient records, and messages between actual patients and doctors.9 The AI chatbot is constantly learning and can be kept up to date on the latest medical research.10 Baidu, a Chinese search engine, utilizes a chatbot named 'Melody' within its Baidu Doctor App.11 When a patient poses a question to the doctor, the chatbot will request appropriate follow-up questions to learn more about the patient's symptoms so the doctor can make a more informed decision on treatment.12

With respect to prognosis, ANNs have assisted in intelligent and insightful medical planning and action on medical patients depending on their respective level of exposures. It has been demonstrated that ANNs can predict survival in patients suffering from breast and colorectal cancer.13 Remarkably, ANNs have recorded significant success; they have been shown to perform better than colorectal surgeons in predicting outcomes in patients with colorectal cancer!

Other AI-based inventions in the field of Medicine include Fuzzy Expert Systems, Evolutionary Computations and Hybrid Intelligent Systems. Fuzzy Expert Systems recognizes the phenomenon of "fifty shades of grey" – the factual reality of subjectivity – the fact that things might vary in their characteristics and outcomes. Fuzzy Expert Systems have excelled in the diagnosis of conditions including lung cancer, acute leukemia, breast cancer, pancreatic cancer, et cetera.14

Evolutionary Computations are essentially concerned with search and optimization.15 The most widely used forms of Evolutionary Computations are the General Algorithms. They work by creating many random solutions to the problem at hand. This population of many solutions will then evolve from one generation to the next, ultimately arriving at a satisfactory solution to the problem. The best solutions are added to the repository while the inferior ones are eliminated. By repeating this process among the better elements, repeated improvements will occur in the population, survive and generate new solutions.

The Hybrid Intelligent Systems is a product of a combination of the advantages of the earlier highlighted AI-based inventions. This has also been used in resolving a number of medical tasks and problems including the diagnosis and prognosis of breast cancer, coronary artery stenosis and control of the depth of anesthesia.16

  1. AI & IP : The Eligibility Question

Flowing from the exposition of the interaction between AI and Medicine, is the common concept of inventiveness. The AI-based Medical solutions highlighted are products of deliberate efforts at creativity and ingenuity. They are clearly inventions; and never before has planet Earth witnessed their sophistication and range of possible applications. They belong to the realm of Intellectual Property Rights (IPRs).

As the impact of AI in Medicine continues to bolster, the intellectual property legal system must gear up for some crucial questions especially regarding the protection of the rights of persons who expend their 'sweats and calories' in seeing to the inventions of these medical solutions. Perhaps, one of the most crucial questions to be answered is that of the eligibility of an AI-based medical solution for patent protection. Are the Nigerian IP laws awake to this occasion? Let's find out.

  1. SubjectMatter Eligibility of AI-Based Medical Solutions

There is a dearth, if not a total vacuum, of IP judicial authorities bordering on this recondite area. This is clearly understandable in view of the nascent and emerging status of AI in the Nigerian IP space, especially in the health sector. Nonetheless, this piece will consider another common law jurisdiction with arguably one of the most vibrant IP legal systems globally, (i.e., the United States) and critically analyse the patentable subject matter of AI vis-à-vis the relevant Nigerian statute.

Under Nigerian Law, the subject matter of an invention must be eligible for patenting. The Nigerian Patents and Designs Act (PDA)17 sets out the criteria for an invention to qualify as patentable. Section 1 PDA provides that an invention may be eligible for patent if such invention:

  1. Is new;
  2. Involves an inventive step;
  3. Is Capable of industrial use or application; and
  4. Is not specifically excluded by the Act.

Some U.S. judicial decisions have made this subject more thought-provoking. In Mayo Collaborative Services v. Prometheus Labs. Inc.,18 for instance, a patent claim was made involving the relationship between the concentrations of certain metabolites in the blood and the likelihood that a drug dosage would prove ineffective or cause harm for failing to meet this requirement. The Court held the invention to be ineligible for patenting as it provided "instructions [that] add nothing specific to the laws of nature other than what is well-understood, routine, conventional activity, previously engaged in by those in the field."19 In essence, the Court was of the judicial opinion that a medical invention would not be eligible for patent registration if it is merely a diagnostic method that only recites an indication or a sign to change dosage.

Similarly, in Alice Corporation Property Limited v. CLS Bank International,20 the Court spelled out a two-prong test for determining the eligibility of an invention for patentability based on its subject matter as follows:

  1. Determine whether the claims are directed to a patent-ineligible concept (laws of nature, abstract ideas, and natural phenomena); and
  2. Determine whether the claim's elements, considered both individually and as an ordered combination, transform the nature of the claims into a patent-eligible application.21

Apparently following the principles in the above cases, in Ariosa Diagnostics Inc. v. Sequenom Inc., the Court admitted that a method of prenatal diagnosis of foetal DNA "reflects a significant human contribution ... that revolutionized prenatal care" but intriguingly held that the claimed method was not eligible for patent.22

In contrast, it appears that a medical invention would be eligible for patent where it is not merely a diagnostic method but also indicates a method of treatment of a disease. This was the crux of the majority decision in Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals.23 Here, the patent was related to a method of treating schizophrenia patients with iloperidone involving prescriptions and dosage based on the patient's genotype. The Court held the invention eligible for patent and noted that the patent claim went above and beyond just diagnosing the patient's genotype to include a capability to disclose specific dosage in the treatment steps of the patient.

It is submitted that the position of the Courts in the United States as revealed above is not likely to be different from a correct interpretation of the PDA in Nigeria. Section 1(4) PDA sets out the grounds upon which an invention may be excluded as follows:

"(4) Patents cannot be validly obtained in respect of-

(a) Plant or animal varieties, or essentially biological processes for the production of plants or animals (other than microbiological processes and their products); or

(b) inventions the publication or exploitation of which would be contrary to public order or morality (it being understood for the purposes of this paragraph that the exploitation of an invention is not contrary to public order or morality merely because its exploitation is prohibited by law).

(5) Principles and discoveries of a scientific nature are not inventions for the purposes of this Act."

For an invention relating to the field of Medicine to be eligible for patent, it would certainly have to scale through these three important exclusionary provisions.

Delving into the first exclusion, where an AI-related invention has its subject matter relating to plant and animal varieties and/or biological processes for the production of plant and animal varieties, such invention would not be eligible for patent under Nigerian law. Also, by virtue of the second exclusion, an invention that violates public order and morality would certainly not be eligible for invention.

Of utmost importance in this context is the third exclusion. Where an invention is based on principles and discoveries of a scientific nature, then such invention would not be eligible for patent. This exclusion looks particularly problematic when placed in relation to the examples earlier highlighted in this treatise. However, the presence of the words "principles" and "discoveries" are suggestive of the position of the United States Courts. For an invention to enjoy eligibility to a grant of Patent, it must not merely relate to the discovery (diagnosis) of a biological situation or state of things but must be capable of creating (inventing) a method through which a scientific challenge or problem can be tackled.

To sum up the foregoing analysis, the below excerpt by an IPL expert is helpful:

"The question may then be asked whether principles and discoveries of a scientific nature are inventions? The Nigerian PDA specifically excludes these and states that they are not inventions. Indeed, a discovery without anything further cannot amount to an invention. A man who discovers that a known machine can produce effects which no one knew could be produced by it before, or that a known process will produce improved effects if continued for a longer period, or who discovers an advantage in the working of a known scientific process without any modification in that process, may make a useful discovery, but if he does nothing more, his discovery is not a patentable invention."24

  1. Review of Subject-Matter Eligibility: Critical Issues

Apart from the substantive issues relating to subject-matter eligibility, medical AI inventions also face practical issues. Indeed, the possibility of a medical invention apparently satisfying the basic requirements for patentability in the PDA but falling short of registration cannot be divorced from the subject matter of patentability.

By section 3 of the PDA, every patent application shall be addressed to the Registrar of Patents in compliance with appropriate procedures and formalities. Notably, section 3 of the PDA prescribes procedures to follow for patent applications especially what the application should contain. In essence, full compliance with section 3 PDA does not automatically secure a patent on the invention.

Also relevantly, section 4 PDA clothes the Registrar of Patents with the power to examine every patent application but only for conformity with section 3 PDA. In clearer terms, this power of the Registrar of Patents to examine patent applications is aimed at ensuring that the content of the patent application as well as the procedure for application are complied with in line with section 3 PDA. The power of the Registrar of Patents clearly has nothing to do with examining a patent application on the merits.25 The PDA states thus:

"(2) Where the examination mentioned in subsection (1) of this subsection shows that a patent application satisfies the requirements of section 3(1) and (3) of this Act, the patent shall be granted as applied for without further examination and, in particular, without examination of the questions-

  • whether the subject of the application is patentable under section 1 of this Act;"26

In essence, by the combined effect of the PDA and the Patent Rules, upon compliance with the procedures and provision as to the content of the application, the Registrar shall grant the patent.27

Understandably, the Registrar of Patents is, with due respect, presumed a layman administrator – one skilled in the statutory patent application formalities but bereft of scientific and technical credentials. The Registrar thus has strictly administrative responsibilities with respect to patent applications and cannot enquire into the merits of compliance of an application with the subject-matter eligibility criteria discussed in preceding paragraphs. The PDA allocates the risk of establishing patentability to the patentee, by making the patentee's proprietary rights subject to the snail-paced and grossly unpredictable vehicle of courtroom litigation.

As F. O. Babafemi notes, there are some IPL jurisdictions where the examination of patent applications are done by the Patent Office and intended to cover all possible aspects of the patent law capable of affecting the validity of such patent, including those of the United States (US) and the United Kingdom (UK), which are in substantial accord with Nigerian laws.28 In these systems, the Registrar of Patents and the agency staff possess scientific expertise and technical skills for conducting very meticulous inquests into the patentable nature of submitted applications that spans fairly lengthy periods of time.

In addition to the lack of substantial examination in the Nigerian patent system highlighted above, the adversarial system of adjudication may restrict the latitude of the Judge's powers to conduct wide-ranging inquisitions on the patent claim which is the subject of litigation, if not properly within the scope of the pleadings as filed. This ultimately has a negative toll on the quality and reliability of the IP dispute resolution system.

It is respectfully submitted that the PDA and subsidiary legislations be amended to include substantial expertise in intellectual property law on patents and designs as an eligibility criteria for the appointment of the Registrar of Patents. In addition, the Registrar of Patents should be empowered to review patent applications on the merits in line with international best practices and the peculiar needs of the Nigerian IPL system. The Registrar of Patents should be able to conduct in-depth and meticulous inquests on the patent claim sought to be registered and its conformity with subject-matter eligibility as well as other statutory criteria.

  1. Conclusion

Admittedly, the impact of AI in the field of Medicine in Nigeria has not been pronounced by Nigerian courts. However, the fact that it took only a few knocks on the door for FinTech and PropTech to gain wide recognition and influence in Nigeria suggests a promising future for this field. The reality of medical practice as a global rather than a municipal field also suggests that it would ultimately penetrate and 'infect' the Nigerian medical practice. The sooner this is grasped, the better for intellectual property law practice and overall, the medical economy.

In addition, the AI revolution is real and here to stay. With the unstoppable prevalence of technological advancement in medicine and other related fields, it would not be surprising that the Registrar of Patents is overburdened with patent applications. The Patent Registry should therefore be enlarged, computerized and adequately staffed in anticipation of this certain occurrence. A crystal ball is not also required to foresee that specialized IP Courts would soon be a national urgency in Nigeria in the near future. Similar to the National Industrial Court, there should be a specialized Court or Tribunal specifically empowered to adjudicate on IP disputes. A system is developed, not necessarily by quality of its laws, but by foresight and appropriate actions.

Footnote

1 Olukolade Ehinmosan, NYSC Intern, Corporate and Capital Markets Department, SPA Ajibade & Co, Lagos, Nigeria.

2 A. N, Ramesh, C. Kambhampati, J. R. T. Monson, P. J. Drew, Artificial Intelligence in Medicine, 86, Annals Royal College Surgeons Eng. 334 (2004), < https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1964229/pdf/15333167.pdf> accessed August 2, 2019 at 5:47 pm.

3 Ibid.

4 Stuart C. Shapiro, Artificial Intelligence, in Shapiro SC (ed.) Encyclopedia of Artificial Intelligence, vol. 1, 2nd ed., New York: Wiley, 1992.

5 Alan M. Turing, Computing Machinery and Intelligence, Mind 1950; 59: 433–60, < https://philpapers.org/rec/TURCMA> accessed August 2, 2019 at 2:58 pm.

6 Gunn AA, The Diagnosis of Acute Abdominal Pain with Computer Analysis, J. R. College Surgeon Edinburgh, 1976; 21: 170–2.

7 A. N, Ramesh, C. Kambhampati, J. R. T. Monson, P. J. Drew, Artificial Intelligence in Medicine, 86, Annals Royal College Surgeons Eng. 335 (2004), < https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1964229/pdf/15333167.pdf> accessed August 3, 2019 at 6:54 pm.

8 Stamey T.A., Barnhill S. D., Zang Z, Effectiveness of ProstAsureTM in Detecting Prostate Cancer (PCa) and Benign Prostatic Hyperplasia (BPH) in Men Age 50 and Older, J Urol 1996; 155: 436A.

9 Jelor Gallego, An AI-Powered Chatbot is Helping Doctors Diagnose Patients, Futurism (Oct. 13, 2016), https://futurism.com/an-aipowered-chatbot-is-helping-doctors-diagnose-patients/ accessed August 1, 2019 at 7:23 am.

10 Artificial Intelligence ChatBots—Explore Intelligence in a Bot!, KatPro, (June 7, 2017) https://katprotech.com/blog/artificial-intelligencechatbots-explore-intelligence-in-bot/> accessed 29th July 2019, 10:54 a.m.

11 Gallego, supra n. 10.

12 Ibid.

13 Burke H. B., Goodman P. H., Rosen D. B., Henson D. E., Weinstein J. N., Harrell Jr. F. E. et al, Artificial Neural Networks Improve the Accuracy of Cancer Survival Prediction, Cancer 1997; 79: 857–62.

14 Angela Torres and Juan J. Nieto, Fuzzy Logic in Medicine and Bioinformatics, Journal of Biomedicine and Biotechnology (2006) < https://www.researchgate.net/profile/Juan_Nieto9/publication/6903835_Fuzzy_Logic_in_Medicine_and_Bioinformatics/links/547ca54d0cf285ad5b088327/Fuzzy-Logic-in-Medicine-and-Bioinformatics.pdf> accessed July 29, 2019 at 11:28 am.

15 A. N, Ramesh, supra, 337.

16 Allen R., Smith D., Neuro-Fuzzy Closed-Loop Control of Depth of Anaesthesia, Artif Intell Med 2001; 21: 185–91.

17 Cap. P2, LFN 2004.

18 566 U.S. 66 (2012).

19 Supra, at 69.

20 134 S. Ct. 2347 (2014).

21 Susan Y. Tull and Paula E. Miller, Patenting Artificial Intelligence: Issues of Obviousness, Inventorship and Patent Eligibility, 313 at 316: Vol. 1, No. 5, The Journal of Robotics, Artificial Intelligence and Law (RAIL), September-October 2018 < https://www.finnegan.com/images/content/1/9/v2/197825/PUBLISHED-The-Journal-of-Robotics-Artificial-Intelligence-L.pdf accessed July 29, 2019 at 02:36 pm

22 788 F.3d, 1371, 1376, 1379 (Federal Circuit, 2015).

23 Federal Circuit, April 13 2018, accessible at https://ocpatentlawyer.com/wp-content/uploads/2018/05/Vanda-Pharmaceuticals-Inc.-v.-Aventisub-LLC.pdf accessed August 16, 2019 at 6:58 pm.

24 F. O. Babafemi, Intellectual Property: The Law and Practice of Copyright, Trade Marks, Patents and Industrial Designs in Nigeria, 1st ed., Justinian Books, p. 348.

25 See also, Rules 11 to 15 of the Patent Rules, a subsidiary legislation made in pursuance of the PDA.

26 Section 4(2), PDA (emphasis intended); also, Rule 13 of the Patent Rules (supra).

27 Section 4(2), PDA and Rule 14 of the Patent Rules (supra).

28 F. O. Babafemi, Intellectual Property: The Law and Practice of Copyright, Trade Marks, Patents and Industrial Designs in Nigeria, 1st ed., Justinian Books, pp. 378-79.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Practice Guides
by Mondaq Advice Centres
Relevancy Powered by MondaqAI
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions